BACK

Other Solid Tumors > Primary glioblastoma multiforme and recurrent glioblastoma multiforme

Clinical trial information


Select trial for more information

Area under investigation,Advanced solid tumors,Primary glioblastoma multiforme and recurrent glioblastoma multiforme=true

ARTEMIDE-subQ trial overview

Tumor

Advanced solid tumor

Trial Identifier

NCT07161414

Phase

I

Stage

Metastatic and/or unresectable

Regimen

Part 1 (Dose Finding, Cohort A and B): Rilvegostomig IV as 1st dose, followed by subsequent treatment with rHu SC and rilvegostomig SC at predefined intervals (DL1 and DL2); Part 2 (Dose confirmation): Rilvegostomig SC + rHu SC

Visit ct.gov
Go

BLUESTAR trial overview

Tumor

Advanced solid tumors (breast cancer, BTCs, ovarian cancer, endometrial cancer, squamous NSCLC)

Trial Identifier

NCT05123482

Phase

I/IIa

Regimen

Puxitatug samrotecan monotherapy; puxitatug samrotecan + rilvegostomig; puxitatug samrotecan + rilvegostomig + palacaparib

Visit ct.gov
Go

CERTIS1 trial overview

Tumor

Advanced solid tumors

Trial Identifier

NCT05417594

Phase

I/IIa

Regimen

Palacaparib monotherapy; palacaparib + temozolomide; [11C]AZ14193391 + palacaparib or [11C]AZ14193391 + palacaparib + temozolomide; palacaparib + T-DXd; palacaparib + Dato-DXd

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.

Go

CLARITY-PanTumor01 trial overview

Tumor

Claudin 18.2-positive advanced solid tumors (gastric/GEJ cancer, pancreatic adenocarcinoma, BTCs)

Trial Identifier

NCT06219941

Phase

II

Regimen

Sonesitatug vedotin; sonesitatug vedotin + chemotherapy

Visit ct.gov
Go

DESTINY-PanTumor02 trial overview

Tumor

Early-stage NSCLC adenocarcinoma following complete surgical resection (R0) that is ctDNA-positive or has high-risk pathological features

Trial Identifier

NCT06564844

Phase

III

Stage

Treatment-naïve Stage I

Regimen

Dato-DXd + rilvegostomig; rilvegostomig; SoC; abc

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of the world.

Go

eVOLVE-02 trial overview

Tumor

Advanced or metastatic tumors (Cervical, HNSCC, pleural mesothelioma, and ESCC)

Trial Identifier

NCT06535607

Phase

II

Regimen

Volrustomig monotherapy; volrustomig + chemotherapy

Visit ct.gov
Go

FONTANA trial overview

Tumor

Advanced solid tumors

Trial Identifier

NCT05797168

Phase

I/IIa

Regimen

Torvutatug samrotecan monotherapy; torvutatug samrotecan + saruparib; torvutatug samrotecan + bevacizumab; torvutatug samrotecan + carboplatin ± bevacizumab; torvutatug samrotecan + palacaparib

Visit ct.gov
Go

NCT03423628 trial overview

Tumor

Primary glioblastoma multiforme and recurrent glioblastoma multiforme

Trial Identifier

NCT03423628

Phase

I

Regimen

AZD1390 + radiotherapy

Visit ct.gov
Go

NCT05877599 trial overview

Tumor

Unresectable, advanced, and/or metastatic NSCLC, colorectal adenocarcinoma, HNSCC, pancreatic adenocarcinoma, breast cancer, or any other solid tumor histologies that are positive for the TP53 R175H mutation

Trial Identifier

NCT05877599

Phase

I

Regimen

NT-175

Visit ct.gov

Sponsored by Neogene Therapeutics, Inc.

Go

NCT06005493 trial overview

Tumor

Advanced or metastatic solid tumors of the GC, GEJC, PDAC and esophageal adenocarcinoma

Trial Identifier

NCT06005493

Phase

I/II

Regimen

AZD5863 (dose escalation and dose expansion)

Visit ct.gov
Go

NCT06218914 trial overview

Tumor

Unresectable, advanced, and/or metastatic NSCLC, colorectal adenocarcinoma, pancreatic adenocarcinoma, endometrial cancer, or any other solid tumor histology that is positive for the KRAS G12D mutation

Trial Identifier

NCT06218914

Phase

I

Regimen

NT-112; AZD0240

Visit ct.gov
Go

NCT06973564 trial overview

Tumor

Advanced solid tumors with KRAS alterations, including CRC, PDAC, NSCLC and other solid tumors

Trial Identifier

NCT06973564

Phase

I/IIa

Regimen

JAB-23E73 monotherapy and chemotherapy combinations

Visit ct.gov

Partnered (Jacobio)

Go

NCT06959615 trial overview

Tumor

Advanced solid tumors harboring KRAS gene alteration

Trial Identifier

NCT06959615

Phase

I/IIa

Regimen

JAB-23E73

Visit ct.gov

Partnered (Jacobio) China only

Go

NCT07115043 trial overview

Tumor

Advanced or metastatic solid tumors, including MEL, NSCLC, SCC, RCC, HNSCC, GC/GEJC, MCC, HGSOC, and TNBC.

Trial Identifier

NCT07115043

Phase

I/II

Stage

Locally advanced or metastatic select solid tumors

Regimen

AZD6750 (IV) as a single agent; AZD6750 + rilvegostomig (IV)

Visit ct.gov
Go

PARTHENON trial overview

Tumor

Advanced/​metastatic homologous recombination deficient solid tumors

Trial Identifier

NCT07446855

Phase

I/IIa

Regimen

AZD4956 monotherapy; saruparib monotherapy; AZD4956 + saruparib

Visit ct.gov
Go

PETRA trial overview

Tumor

Advanced solid tumors (advanced/metastatic ovarian cancer, HR+/HER2- breast cancer, TNBC, pancreatic cancer, prostate cancer, NSCLC, SCLC, gastric cancer, biliary cancer, cervical cancer, endometrial cancer, CRC, bladder cancer)

Trial Identifier

NCT04644068

Phase

I/IIa

Regimen

Saruparib; saruparib + paclitaxel; saruparib + carboplatin ± paclitaxel; saruparib + T-DXd; saruparib + Dato-DXd; saruparib + camizestrant

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.

Go

PRIMROSE trial overview

Tumor

MTAP-deficient advanced solid tumors

Trial Identifier

NCT06130553

Phase

I/IIa

Regimen

AZD3470; AZD3470 + Dato-DXd; Dato-DXd

Visit ct.gov
Go

RHEA-1 trial overview

Tumor

Advanced or metastatic solid tumors which are GPC3+

Trial Identifier

NCT06795022

Phase

I/II

Stage

Advanced recurrent and/or metastatic and/or unresectable  HCC

Regimen

AZD9793 (T cell-engaging antibody that targets GPC3 on tumor cells) intravenous monotherapy; AZD9793 subcutaneous monotherapy

Visit ct.gov
Go

SubQ (NCT07015697) trial overview

Tumor

HER2-expressing metastatic solid tumors

Trial Identifier

NCT07015697

Phase

I

Regimen

Subcutaneous T-DXd + hyaluronidase

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world. This study is sponsored by Daiichi Sankyo, Inc.

Go

SubQ (NCT07391670) trial overview

Tumor

Solid tumours including NSCLC, HCC or LS-SCLC​

Trial Identifier

NCT07391670

Phase

I

Regimen

Durvalumab + rHu SC, durvalumab IV, tremelimumab IV

Visit ct.gov
Go

TROPION-PanTumor01 trial overview

Tumor

Advanced solid tumors including advanced/metastatic NSCLC, TNBC, HR-positive/HER2-negative breast cancer, HER2-low breast cancer, and other solid tumors

Trial Identifier

NCT03401385

Phase

I

Regimen

Dato-DXd

Visit ct.gov

This study is sponsored by Daiichi Sankyo, Inc.

Go

TROPION-PanTumor03 trial overview

Tumor

Advanced solid tumors (endometrial, gastric, mCRPC, ovarian, colorectal, metastatic urothelial carcinoma, BTCs)

Trial Identifier

NCT05489211

Phase

II

Regimen

Dato-DXd; Dato-DXd + capecitabine or 5-FU; Dato-DXd + prednisone or prednisolone; Dato-DXd + carboplatin + bevacizumab followed by Dato-DXd + bevacizumab; Dato-DXd + bevacizumab + (5-FU + leucovorin or capecitabine); Dato-DXd+ 5-FU/leucovorin or capecitabine + bevacizumab; Dato-DXd + rilvegostomig or carboplatin/cisplatin

Visit ct.gov
Go

Some compounds herein refer to selected AstraZeneca pipeline products still under development. AstraZeneca pipeline products are investigational products and, as such, are not approved by the US Food & Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory agency for the uses under investigation. Information regarding these investigational products should, under no circumstances, be regarded as a recommendation for their use or of their safety or efficacy.

This site is intended for US Healthcare Professionals.

Veeva ID: Z4-84958 US-109129 DE-92568 Last Updated October 20263/26
©2026 AstraZeneca. All rights reserved.